[go: up one dir, main page]

AR133935A1 - Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo - Google Patents

Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo

Info

Publication number
AR133935A1
AR133935A1 ARP240102581A ARP240102581A AR133935A1 AR 133935 A1 AR133935 A1 AR 133935A1 AR P240102581 A ARP240102581 A AR P240102581A AR P240102581 A ARP240102581 A AR P240102581A AR 133935 A1 AR133935 A1 AR 133935A1
Authority
AR
Argentina
Prior art keywords
tumors
same
cancer
prevention
treatment
Prior art date
Application number
ARP240102581A
Other languages
English (en)
Inventor
Youngku Kang
Sang Jun Park
Seul Lee
Ahreum Kwon
Bora Yoo
Ji Duck Kim
Joon Seok Park
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of AR133935A1 publication Critical patent/AR133935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente divulgación se refiere a un compuesto representado por la siguiente Fórmula Química (1), o una sal farmacéuticamente aceptable del mismo, y el compuesto de acuerdo con la presente divulgación se puede utilizar favorablemente para prevenir o tratar el cáncer o los tumores. Fórmula Química (1), en donde en la Fórmula Química (1), L y R¹ a R⁴ son los mismos que se definen en la descripción detallada.
ARP240102581A 2023-09-25 2024-09-25 Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo AR133935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20230128347 2023-09-25

Publications (1)

Publication Number Publication Date
AR133935A1 true AR133935A1 (es) 2025-11-19

Family

ID=95203443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102581A AR133935A1 (es) 2023-09-25 2024-09-25 Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo

Country Status (4)

Country Link
KR (1) KR20250045486A (es)
AR (1) AR133935A1 (es)
TW (1) TW202521112A (es)
WO (1) WO2025071172A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002060A (es) * 2008-08-25 2011-04-05 Irm Llc Moduladores de la senda de hedgehog.
CN106459007B (zh) * 2014-06-17 2020-02-28 韩国化学研究院 嘧啶-2，4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物
US20220289712A1 (en) * 2019-08-21 2022-09-15 Beigene, Ltd. Aminopyrazine compounds as hpk1 inhibitor and the use thereof
CN116854687B (zh) * 2021-03-23 2025-07-25 杭州阿诺生物医药科技有限公司 Hpk1激酶抑制剂化合物
CN118434729A (zh) * 2022-01-11 2024-08-02 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物

Also Published As

Publication number Publication date
KR20250045486A (ko) 2025-04-01
TW202521112A (zh) 2025-06-01
WO2025071172A1 (ko) 2025-04-03

Similar Documents

Publication Publication Date Title
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
AR129238A1 (es) Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras
CL2025001072A1 (es) Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer.
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
CO2020004087A2 (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CO2024011199A2 (es) Composiciones y métodos para inhibir el factor b del complemento
MX2024002409A (es) Terapias contra el cancer.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CO2024001017A2 (es) Compuestos terapéuticos y procedimientos
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CL2022002641A1 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
AR133935A1 (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
AR133526A1 (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
DOP2025000090A (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
CO2024009030A2 (es) Composición farmacéutica para prevenir o tratar cáncer de mama triple negativo
AR127582A1 (es) Métodos para el tratamiento del cáncer